Darwin Global Management, Ltd. Buys BioNTech SE, Inhibrx Inc, Adagio Therapeutics Inc, Sells Intellia Therapeutics Inc, Beam Therapeutics Inc, ESSA Pharma Inc

• New Purchases: BNTX, ADGI, VIR, FULC, AVTE,
• Added Positions: XLRN, INBX, FATE,
• Reduced Positions: NTLA, BBIO, VERV, ACRS,
• Sold Out: BEAM, EPIX, KROS, RLAY, GBIO,

For the details of Darwin Global Management, Ltd.'s stock buys and sells, go to https://www.gurufocus.com/guru/darwin+global+management%2C+ltd./current-portfolio/portfolio

1. Acceleron Pharma Inc (XLRN) - 2,000,000 shares, 63.36% of the total portfolio. Shares added by 13.61%
2. Intellia Therapeutics Inc (NTLA) - 752,024 shares, 18.57% of the total portfolio. Shares reduced by 59.57%
3. BioNTech SE (BNTX) - 132,932 shares, 6.68% of the total portfolio. New Position
4. Fate Therapeutics Inc (FATE) - 353,250 shares, 3.85% of the total portfolio. Shares added by 5.16%
5. Inhibrx Inc (INBX) - 542,586 shares, 3.33% of the total portfolio. Shares added by 140.64%

Darwin Global Management, Ltd. initiated holding in BioNTech SE. The purchase prices were between $205.93 and $447.23, with an estimated average price of $316.66. The stock is now traded at around $254.010000. The impact to a portfolio due to this purchase was 6.68%. The holding were 132,932 shares as of 2021-09-30.

Darwin Global Management, Ltd. initiated holding in Adagio Therapeutics Inc. The purchase prices were between $20.88 and $56.08, with an estimated average price of $37.24. The stock is now traded at around $20.130000. The impact to a portfolio due to this purchase was 0.67%. The holding were 86,528 shares as of 2021-09-30.

Darwin Global Management, Ltd. initiated holding in Vir Biotechnology Inc. The purchase prices were between $34.9 and $54.54, with an estimated average price of $43.35. The stock is now traded at around $33.910000. The impact to a portfolio due to this purchase was 0.36%. The holding were 45,311 shares as of 2021-09-30.

Darwin Global Management, Ltd. initiated holding in Fulcrum Therapeutics Inc. The purchase prices were between $7.28 and $30.97, with an estimated average price of $18.95. The stock is now traded at around $18.070000. The impact to a portfolio due to this purchase was 0.18%. The holding were 33,997 shares as of 2021-09-30.

Darwin Global Management, Ltd. initiated holding in Aerovate Therapeutics Inc. The purchase prices were between $11.76 and $22.49, with an estimated average price of $16.12. The stock is now traded at around $16.710000. The impact to a portfolio due to this purchase was 0.05%. The holding were 12,484 shares as of 2021-09-30.

Darwin Global Management, Ltd. added to a holding in Inhibrx Inc by 140.64%. The purchase prices were between $25.18 and $37.81, with an estimated average price of $30.45. The stock is now traded at around $43.670000. The impact to a portfolio due to this purchase was 1.95%. The holding were 542,586 shares as of 2021-09-30.

Darwin Global Management, Ltd. sold out a holding in Beam Therapeutics Inc. The sale prices were between $84.37 and $133.6, with an estimated average price of $101.1.

Darwin Global Management, Ltd. sold out a holding in ESSA Pharma Inc. The sale prices were between $7.76 and $29.37, with an estimated average price of $15.99.

Darwin Global Management, Ltd. sold out a holding in Keros Therapeutics Inc. The sale prices were between $29.27 and $43.71, with an estimated average price of $35.63.

Darwin Global Management, Ltd. sold out a holding in Relay Therapeutics Inc. The sale prices were between $29.75 and $37.99, with an estimated average price of $33.69.

Darwin Global Management, Ltd. sold out a holding in Generation Bio Co. The sale prices were between $20 and $27.43, with an estimated average price of $23.99.